News
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...
In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
Novo Nordisk's new CEO, Maziar Mike Doustdar, faces challenges in reviving waning sales and shares in the weight-loss drug ...
Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback